新辅助化疗后临床分期升级影响保留阴道膀胱切除术资格:识别可能受益于中期影像评估的膀胱癌患者
回顾性分析89例接受新辅助化疗(NAC)及根治性膀胱切除术的女性非转移性肌层浸润性膀胱癌(MIBC)患者,75例有NAC前后影像。NAC后6/75(8%)出现临床分期升级,其中三角区肿瘤患者中2/39(5%)进展且最终病理均为pT4(阴道侵犯),失去保留阴道手术资格。中期影像评估可能识别无应答者并保留保留阴道根治性膀胱切除术的资格。
要点
- NAC后临床分期升级总体发生率8%(6/75),三角区肿瘤患者中5%(2/39)进展至阴道侵犯(pT4)。
- 三角区肿瘤患者中,NAC后9例降期、2例升级、28例无变化。
- 中期影像评估可能识别无应答者,保留保留阴道根治性膀胱切除术的资格。
核心结论
- NAC后临床分期升级不常见,但5%的三角区MIBC患者因进展而失去保留阴道膀胱切除术资格。
- 中期影像评估可能识别无应答者并保留保留阴道根治性膀胱切除术的资格。
研究设计与样本
- 回顾性分析2012年至2023年接受NAC及根治性膀胱切除术的89例女性非转移性MIBC患者。
- 肿瘤位置根据经尿道膀胱肿瘤电切术手术记录确定,NAC前后临床分期根据影像确定。
主要发现
- 75/89例患者有NAC前后影像;55例临床分期无变化,6例升级(4例cT2→cT3,2例cT3→cT4),14例降期(13例cT3→cT2,1例cT4→cT2)。
- 75例有NAC前后影像的患者中39例为三角区肿瘤;其中28例无变化,2例升级(1例cT2→cT3,1例cT3→cT4),9例降期(8例cT3→cT2,1例cT4→cT2)。
- 总体6/75(8%)患者NAC后出现临床分期升级。
- 三角区肿瘤患者中2/39(5%)NAC后临床进展,最终病理均为pT4(阴道侵犯)。
临床怎么用
- 作者认为,中期影像评估可能识别无应答者并保留保留阴道根治性膀胱切除术的资格。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Limited data exist on the frequency with which clinical progression during neoadjuvant chemotherapy (NAC) for muscle-invasive bladder cancer (MIBC) impacts eligibility for a vaginal-sparing surgical approach or on the utility of interim imaging assessment. We sought to evaluate the incidence of clinical upstaging following NAC that would render a patient ineligible for a vaginal-sparing cystectomy. METHODS: Eighty-nine female patients with non-metastatic MIBC treated with NAC and radical cystectomy (RC) (2012-2023) were retrospectively reviewed. Tumor location(s) was determined from transurethral resection of bladder tumor operative reports. Pre- and post-NAC clinical staging was determined from imaging. Outcomes of interest included clinical upstaging and upstaging to vaginal invasion after NAC. RESULTS: 75/89 patients had pre- and post-NAC imaging. Fifty-five had no change in clinical staging, 6 patients were upstaged (4 cT2→cT3, 2 cT3→cT4), and 14 patients were downstaged (13 cT3→cT2, 1 cT4→cT2). Of the 75 patients with pre- and post-NAC imaging, 39 had trigone tumors. Of these, 28 had no change in clinical staging, 2 were upstaged (1 cT2→cT3, 1 cT3→cT4) and 9 were downstaged (8 cT3→cT2, 1 cT4→cT2). Overall, 6/75 (8%) of patients demonstrated clinical upstaging after NAC. 2/39 (5%) of patients with trigone tumors clinically progressed after NAC and both had vaginal invasion (pT4) on final pathology. CONCLUSION: Although clinical upstaging after NAC was infrequent, 5% of patients with trigonal MIBC were rendered ineligible for vaginal-sparing cystectomy following NAC due to progression. Interim imaging assessment may identify non-responders and preserve eligibility for vaginal-sparing RC.
引用
- Liu WJ, Campbell RA, Michael PD, et al. Clinical Upstaging After Neoadjuvant Chemotherapy Impacting Eligibility for Vaginal-sparing Cystectomy: Identifying Bladder Cancer Patients Who May Benefit From Interim Imaging. Urology. 2024. PMID: 38908561. doi:10.1016/j.urology.2024.06.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。